Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
PARSIPPANY, N.J., June 01, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the Jefferies 2017 Global Healthcare Conference at 1:30 PM ET on Tuesday, June 6, 2017 in New York City.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco (973) 451-4030 [email protected]
